n>3SBio Inc.Unaudited first half consolidated statements of income(expressed in thousands, except per share , per ADS and other share and ADS data)
For the Six Months EndedFor the Six Months EndedJune 30, 2010June 30, 2011RMBUS$RMBUS$(unaudited)(unaudited)(unaudited)(unaudited)Net Revenues:EPIAO
120,009
17,697148,976
23,049TPIAO
62,120
9,16080,031
12,382Intefen
2,573
3792,570
398Inleusin
1,033
1521,370
212Iron sucrose
8,577
1,26511,061
1,711Export
5,982
8828,746
1,353Others
1,574
2321,613
250Total net revenues
201,868
29,767254,367
39,355Cost of revenues(17,927)
(2,644)(29,960)
(4,635)Gross profit183,941
27,123224,407
34,720Operating expensesResearch and development costs
(10,423)
(1,537)(18,436)
(2,852)Sales, marketing and distribution expenses
(90,803)
(13,390)(120,674)
(18,670)General and administrative expenses
(26,573)
(3,918)(31,037)
(4,802)Total operating expenses
(127,799)
(18,845)(170,147)
(26,324)Operating income 56,142
8,27854,260
8,396Interest income
5,795
8558,727
1,350Grant income
187
281,187
184Gain/(loss) from investment in non-consolidated affiliates
(126)
(19)20
3Other income, net
862
1271,565
242Total other income, net6,718
99111,499
1,779Income before income tax expense
62,860
9,26965,759
10,175Income tax expense
(10,685)
(1,576)(13,245)
'/>"/>
SOURCE 3SBio Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Related medicine technology :1.
3SBio Inc. Schedules Unaudited Second Quarter 2011 Results2.
3SBio Inc. Announces SFDA Approval of High-Dose EPIAO3.
3SBio Announces Conversion of Isotechnika Debenture4.
3SBio Inc. Schedules Third Quarter 2010 Unaudited Financial Results5.
3SBio Announces Partial Conversion of Isotechnika Debenture6.
3SBio Announces Investor Conference Schedule7.
3SBio and Isotechnika Pharma Announce Strategic Partnership to Develop and Commercialize Voclosporin in China8.
3SBio Inc. Announces Results of Annual General Meeting9.
NewCardio Announces Financial Results for Its 2011 Second Quarter10.
Dehaier Medical Announces Record Second Quarter 2011 Financial Results11.
Emdeon Announces Support for Electronic Prescribing of Controlled Substances Using the DEA-Allowed Quicker-to-Market Approach